Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07785141 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Spectroscopic Assessment of Myocardial Oxygenation Changes in Pediatric Heart Surgery

StatusRecruiting
PhaseNot specified
SponsorSpectrocor
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 1, 2026 to Sep 17, 2026
    • Secondary endpoints: details revised at 3 of 4 entries
    • Publications: details revised at 17 of 18 entries
    • Eligibility criteria expanded, about 3 words
  2. Minor Secondary endpoints: details revised at 2 of 4 entries
    • Study description shortened, about 9 words
    v2
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
8,786 trials monitored
See 412 trials at risk
The goal of this observational study is to investigate the ability of the SpectroCor Tissue Oxygenation Monitor and its accessory SpectroCor Sensor to observe and monitor changes in cardiac oxygen availability in pediatric patients during open-heart surgery. Patients of less than 18 years old who, and whose guardian(s), when applicable according to national legislation, have signed the informed consent, can participate in the study. The primary hypothesis is that the SpectroCor Tissue Oxygenation Monitor and its accessory SpectroCor Sensor can detect myocardial oxygen availability in pediatric open-heart surgery patients. It is expected that the detected tissue oxygenation timely correlates with procedures affecting myocardial perfusion and other clinical parameters during the operation. The secondary hypothesis is that the SpectroCor Tissue Oxygenation Monitor and its accessory, the SpectroCor Sensor, are safe to use, and their usability is acceptable. No comparison group is included in the study. The devices are used by the study investigators during open-heart surgery to collect myocardial tissue spectrometer data from the pediatric population to validate and potentially further develop the monitor and its accessory, the sterile sensor. The follow-up period for each participant ends with discharge from the hospital. No data (such as questionnaires) are obtained directly from the study participants.
Trial Details
NCT Number NCT07785141
Lead Sponsor Spectrocor
Collaborators: Hospital District of Helsinki and Uusimaa
Conditions
(from sponsor)
Myocardial Ischemia, Heart Defects, Congenital, Reperfusion Injury, Myocardial
Related terms Heart Defects, Congenital, Myocardial Ischemia, Myocardial Reperfusion Injury
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov